Difference between revisions of "Legal Restrictions for Biotech increasing in certain countries, decreasing in others"
Jump to navigation
Jump to search
Ruthdonners (talk | contribs) m (→Enablers:) |
(686dH5 <a href="http://cjbskxoyxglr.com/">cjbskxoyxglr</a>, [url=http://mevceqfyonvs.com/]mevceqfyonvs[/url], [link=http://jlqacxwlwcng.com/]jlqacxwlwcng[/link], http://cmrpsnjtqjtt.com/) |
||
Line 2: | Line 2: | ||
'''<br><br> | '''<br><br> | ||
= | 686dH5 <a href="http://cjbskxoyxglr.com/">cjbskxoyxglr</a>, [url=http://mevceqfyonvs.com/]mevceqfyonvs[/url], [link=http://jlqacxwlwcng.com/]jlqacxwlwcng[/link], http://cmrpsnjtqjtt.com/ | ||
==Enablers:== | ==Enablers:== |
Revision as of 09:38, 29 May 2010
This page is being edited by Ruth Donners EMBA09. In case of any questions/remarks contact me.
686dH5 <a href="http://cjbskxoyxglr.com/">cjbskxoyxglr</a>, [url=http://mevceqfyonvs.com/]mevceqfyonvs[/url], [link=http://jlqacxwlwcng.com/]jlqacxwlwcng[/link], http://cmrpsnjtqjtt.com/
Enablers:
- Biotech is seen as a core topic and core industry in many countries economic policy
- Breakthrough in this technology
- Increasing competition from Emerging Markets (Production and R&D Outsourcing)
- National Prestige of a coutnry, willing to be the front-runner
- Harmonisation efforts on a global level regardig approval authorities
- The increasing globalization of markets
Inhibitors:
- Increasing security concerns regarding biotech
- Recalls of drugs from the market (Vioxx, Tysabri)
- Approval Authorities getting more strict
- Monitoring requirements after market launch getting more strict
Paradigms:
- What cannot be done in one part of the world can (an will) be done in another
- Biotechnology technological advances run in front of the ethical discussion on its use
- Biotechnology solutions might be the next big thing for the pharmaceutical industry, eg. gene therapy
Experts:
- Governmental regulatory bodies, eg Food and Drug Administration US
- World Health Organisation
- World Trade Organisation
- Universities doing research in biotech
- Pharmaceutical companies
- Biotech startups
Timing:
- 25.04.1953: Nature publishes Watson and Crick's article on the double helix of DNA [3]
- 06.1995: Birth of Dolly
- 02.2003: Death of Dolly (normal life expectation of a sheep: 12-14 years)
- 28.2.05: Tysabri: Suspension of sale, followed by market withdrawal
- 30.09.04: Vioxx: Withdrawn from the market
- 20.05.05: Veto of US President Bush against Stem Cell Research Bill
- 2005: Birth of Snuppy, the cloned dog
- 2009: Barack Obama becomes president of the USA with a desire to reform the health system